knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 23:02:05 - browse：11652

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Bird flu outbreak in cows is latest avian flu curveball

WSS

Ionis has late

Element Biosciences CEO lays out genome sequencing strategy

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Bird flu in milk supply is likely coming from asymptomatic cows

Listen: Who gets the credit for GLP

Researchers use wearables data and AI to predict preterm birth risk

knowledge

knowledge

focus

United colonoscopy coverage change 'may cost lives,' doctors say

FDA advisers vote against ALS treatment from BrainStorm

BioMarin wins approval for gene therapy to treat hemophilia A

Getting Alzheimer's drug Leqembi to patients can be a challenge

Hollywood unions extend contract negotiations for actors

Diversity in clinical trials starts with building trust, experts say

Trump demands the U.S. pay no more for drugs than other countries … again

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

What does generative AI mean for health care? We asked experts

Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

Bird flu in milk supply is likely coming from asymptomatic cows

Address the ethical violations that led to 'Three Identical Strangers'

How one patient went off dialysis — and others can too

Shingles, which affected Dianne Feinstein, is on the rise

MultiPlan and major insurers sued for alleged medical price

Cancer researcher Catriona Jamieson is sending tumors into space

entertainment

focus

leisure time

explore